Stockscreener 앱 받기
576.07
3.42%
19.05
시간 외 거래:
574.71
-1.36
-0.24%
전일 마감가:
$557.02
열려 있는:
$560.91
하루 거래량:
616.18K
Relative Volume:
0.96
시가총액:
$45.44B
수익:
$4.45B
순이익/손실:
$1.10B
주가수익비율:
42.39
EPS:
13.591
순현금흐름:
$1.06B
1주 성능:
+3.13%
1개월 성능:
+0.54%
6개월 성능:
-19.47%
1년 성능:
+10.66%
1일 변동 폭
$558.14
$581.37
1주일 범위
$536.14
$581.37
52주 변동 폭
$513.02
$769.98
아이덱스 래버러토리스 Stock (IDXX) Company Profile
명칭
Idexx Laboratories Inc
전화
(207) 556-0300
주소
ONE IDEXX DRIVE, WESTBROOK, ME
Compare IDXX vs TMO, DHR, NTRA, A
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IDXX
Idexx Laboratories Inc
|
576.07 | 43.94B | 4.45B | 1.10B | 1.06B | 13.59 |
TMO
Thermo Fisher Scientific Inc
|
543.19 | 198.93B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
205.01 | 142.11B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
269.83 | 39.72B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
136.10 | 38.05B | 7.23B | 1.41B | 1.09B | 4.979 |
아이덱스 래버러토리스 Stock (IDXX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-15 | 개시 | Citigroup | Neutral |
| 2025-12-09 | 개시 | Barclays | Overweight |
| 2025-10-31 | 업그레이드 | Stifel | Hold → Buy |
| 2025-10-01 | 개시 | UBS | Neutral |
| 2025-08-05 | 재확인 | BTIG Research | Buy |
| 2025-07-01 | 개시 | Jefferies | Buy |
| 2024-12-02 | 개시 | Leerink Partners | Outperform |
| 2024-07-25 | 개시 | BTIG Research | Buy |
| 2024-01-30 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2023-12-07 | 개시 | Exane BNP Paribas | Outperform |
| 2023-12-04 | 업그레이드 | Cleveland Research | Neutral → Buy |
| 2023-08-02 | 다운그레이드 | Atlantic Equities | Overweight → Neutral |
| 2022-07-25 | 다운그레이드 | Stifel | Buy → Hold |
| 2022-07-21 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-07-12 | 개시 | Piper Sandler | Overweight |
| 2022-05-05 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-02-08 | 개시 | Atlantic Equities | Overweight |
| 2021-11-18 | 개시 | Morgan Stanley | Overweight |
| 2021-08-05 | 재개 | Credit Suisse | Outperform |
| 2021-07-12 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-02-17 | 개시 | Barclays | Overweight |
| 2019-09-09 | 개시 | Goldman | Neutral |
| 2019-05-23 | 개시 | Guggenheim | Buy |
| 2018-11-02 | 재확인 | BofA/Merrill | Buy |
| 2018-05-07 | 재확인 | Stifel | Buy |
| 2018-01-16 | 개시 | Piper Jaffray | Overweight |
| 2017-08-23 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2017-07-28 | 업그레이드 | CL King | Neutral → Buy |
| 2017-02-03 | 다운그레이드 | Feltl & Co. | Hold → Sell |
| 2016-09-29 | 재개 | BofA/Merrill | Neutral |
| 2016-08-16 | 재확인 | Stifel | Buy |
| 2016-08-03 | 업그레이드 | Northcoast | Sell → Neutral |
| 2016-07-20 | 재확인 | Canaccord Genuity | Buy |
| 2016-04-19 | 재확인 | Canaccord Genuity | Buy |
| 2016-04-01 | 개시 | CL King | Neutral |
| 2016-03-21 | 재확인 | Stifel | Buy |
| 2016-02-04 | 개시 | Credit Suisse | Outperform |
| 2015-10-29 | 재확인 | Stifel | Buy |
| 2015-08-28 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2015-08-13 | 재확인 | Stifel | Buy |
| 2015-07-23 | 재확인 | Canaccord Genuity | Buy |
모두보기
아이덱스 래버러토리스 주식(IDXX)의 최신 뉴스
Idexx Laboratories (IDXX) Shows Promising Growth Potential - GuruFocus
Is IDEXX Laboratories Inc (IDXX) a Bargain After 4.2% Drop? GF Value Says Undervalued - GuruFocus
IDEXX Laboratories Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
IDEXX Laboratories earnings preview: What to expect - MSN
Donald TrumpIDEXX LABS UNSOLICITED Trump Trade on Mar. 23, 2026 - Quiver Quantitative
IDEXX Laboratories stock holds steady as diagnostics demand supports long-term growth - ad-hoc-news.de
IDEXX Laboratories Earnings Preview: What to Expect - Yahoo Finance
Leerink Partners Adjusts IDEXX Laboratories Price Target to $715 From $725, Maintains Outperform Rating - marketscreener.com
Veterinary Lab Automation Global Market Report 2023 Now Available, Covers Asia-Pacific, North America, Europe, and More - GlobeNewswire Inc.
IDEXX Laboratories focuses on diagnostics growth. Investors watch demand trends - ad-hoc-news.de
IDEXX Laboratories Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
IDEXX Laboratories extends its diagnostics reach as a key S&P 500 health-tech name - ad-hoc-news.de
IDEXX Laboratories Does Not Need More Vet Visits, But It Needs More Tests Per Visit (IDXX) - Seeking Alpha
William Blair Maintains IDEXX Laboratories Inc(IDXX.US) With Buy Rating - Moomoo
IDEXX Laboratories focuses on diagnostics growth. Business model supports long-term demand - ad-hoc-news.de
IDEXX Laboratories Inc. stock outperforms competitors on strong trading day - MarketWatch
IDEXX Laboratories Stock: $876 Target Backed by Cancer Dx Adoption Across 7,500 Practices - TIKR.com
IDEXX Laboratories stock holds its focus on diagnostics. Investors watch the business mix. - AD HOC NEWS
IDEXX Laboratories, Inc. (IDXX) Stock Analysis: Exploring a Potential 27% Upside for Investors - DirectorsTalk Interviews
The SNAP Pro AnalyzerIDEXX Laboratories leans on faster point-of-care diagnostics - ad-hoc-news.de
IDEXX Laboratories stock tracks its core diagnostics business - ad-hoc-news.de
IDXXIdexx Laboratories Inc Volatility & Greeks - Finviz
Enterprise value to EBIT forward of IDEXX Laboratories, Inc. – NASDAQ:IDXX - TradingView
IDEXX Laboratories stock leans on its diagnostics base - Ad-hoc-news.de
IDEXX Laboratories focuses on diagnostics growth as investors watch long-term demand - ad-hoc-news.de
Price to sales forward of IDEXX Laboratories, Inc. – NASDAQ:IDXX - TradingView
IDEXX Laboratories outlook as a diagnostics leader - ad-hoc-news.de
Price to earnings forward of IDEXX Laboratories, Inc. – NASDAQ:IDXX - TradingView
Does IDEXX Laboratories (NASDAQ:IDXX) Deserve A Spot On Your Watchlist? - Moomoo
EULAV Asset Management's IDEXX Laboratories Inc(IDXX) Holding History - GuruFocus
IDEXX Laboratories Inc (IDXX) Stock Up 3.8% and Still Undervalued -- GF Score: 96/100 - GuruFocus
IDEXX Laboratories to Release 2026 Second Quarter Financial Results - 01net
Press Release: IDEXX Laboratories to Release 2026 Second Quarter Financial Results - Moomoo
IDEXX Laboratories Inc. stock underperforms Monday when compared to competitors - MarketWatch
IDEXX Laboratories, Inc.(NasdaqGS: IDXX) added to Russell Midcap Value Benchmark - marketscreener.com
Is the Options Market Predicting a Spike in IDEXX Laboratories Stock? - Zacks Investment Research
Is IDEXX Laboratories stock underperforming the Nasdaq? - MSN
IDEXX Laboratories (IDXX) Stock Analysis: Uncovering a Potential 28.58% Upside for Investors - DirectorsTalk Interviews
IDEXX Laboratories with a clear strategy focus, shares anchored in the NASDAQ-100 - AD HOC NEWS
IDEXX Laboratories, Inc.(NasdaqGS: IDXX) added to Russell 1000 Value Benchmark - marketscreener.com
The Catalyst Dx from IDEXX Laboratories Inc.compact chemistry analyzer for fast in-clinic results - AD HOC NEWS
IDEXX Laboratories, Inc.(NasdaqGS: IDXX) added to Russell 1000 Value-Defensive Index - marketscreener.com
IDEXX Laboratories opens the week with a clear consensus, NASDAQ-100 shares in a steady trend - Ad-hoc-news.de
IDEXX Laboratories focuses on long-term growth, shares in NASDAQ-100 healthcare peer group - Ad-hoc-news.de
New diagnostic test for kidney injury - DVM360
IDEXX Laboratories opens the week with earnings focus, shares steady - Ad-hoc-news.de
IDEXX Laboratories, Inc. Actuals & Estimates (NASDAQ:IDXX) - TradingView
IDEXX Laboratories, Inc. Actuals & Estimates (VIE:IDXX) - TradingView
IDXX Forecast — Price Target — Prediction for 2027 - TradingView
IDEXX Laboratories sets the pace with raised 2026 guidance, analysts back the stock - Ad-hoc-news.de
Enterprise value to EBITDA forward of IDEXX Laboratories, Inc. – DUS:IX1 - TradingView
아이덱스 래버러토리스 (IDXX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.72%
1.03%
자본화:
|
볼륨(24시간):